New patent for Lantheus Medcl drug DEFINITY
Annual Drug Patent Expirations for DEFINITY Definity is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are nine patents…
Source
Annual Drug Patent Expirations for DEFINITY Definity is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are nine patents…
Source
Annual Drug Patent Expirations for DEFINITY+RT Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are nine…
Source
Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen…
Source
Annual Drug Patent Expirations for IMBRUVICA Imbruvica is a drug marketed by Pharmacyclics Llc and is included in three NDAs. It is available from one supplier. There are forty-one patents…
Source
Annual Drug Patent Expirations for JORNAY+PM Jornay Pm is a drug marketed by Ironshore Pharms and is included in one NDA. It is available from one supplier. There are fifteen…
Source
Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are ten…
Source
Annual Drug Patent Expirations for BIKTARVY Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are twelve…
Source
Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen…
Source
Annual Drug Patent Expirations for TYVASO Tyvaso is a drug marketed by United Therap and is included in two NDAs. It is available from one supplier. There are eleven patents…
Source
Annual Drug Patent Expirations for TYVASO+DPI Tyvaso Dpi is a drug marketed by United Therap and is included in one NDA. It is available from one supplier. There are eight…
Source